BioSpace News Archive

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis.

Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc.

On August 2, 2023 the New Jersey Board of Education adopted, in a narrow 6 to 5 vote, new rules framed as amendments promoting “Equity in Education.” A letter from the Association of American Physicians and Surgeons urges the board to immediately reverse the amendments.

Aegle Therapeutics Corp. today announced the first patient has been dosed in the Phase 1/2a clinical trial of AGLE-102™ for the treatment of severe second-degree burns.

Chimerix (NASDAQ:CMRX) today announced the publication of data in support of the Company’s first-in-class small molecule imipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas (H3K27M-DMG) in the peer-reviewed journal, Cancer Discovery, a journal of the American Association for Cancer Research.

In response to the opioid crisis, researchers at Hospital for Special Surgery (HSS) are looking for alternate ways to reduce pain after orthopedic procedures.

Bristol Myers Squibb (NYSE: BMY) today announced updated results from the registrational TRIDENT-1 study, demonstrating that repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), continued to show high response rates and durable responses in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

The WBB Research Institute (WBBRI) recently hosted a two-part, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient’s own T-Cells to fight cancer. CAR-T and next generation cell therapies represent a considerable advance in oncology therapy.

10xBio , LLC announced today that it has completed enrollment in a repeat treatment study of its novel injectable drug for submental body contouring.

DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive.